Researchers designed a pre-built warehouse of tumor-associated peptides for personalized CLL vaccines, bypassing the need for costly individualized vaccine design.
Clinical trial NCT04688385 launchedThe peptide warehouse approach moved from laboratory development directly to a first-in-human clinical trial for chronic lymphocytic leukemia.
What the researchers found
The team used mass spectrometry to compare protein fragments displayed on CLL cells versus normal tissue. They found several tumor-associated fragments that appeared often across many CLL patients.
These fragments triggered immune responses from both existing and newly created T cells in CLL patients and healthy volunteers. The researchers packaged these peptides into a pre-made warehouse, so doctors could quickly assemble a personalized multi-peptide vaccine for each patient without starting from scratch.
This matters because CLL has very few mutations, making it hard to find unique cancer targets. The warehouse approach sidesteps this problem by using non-mutated but tumor-associated peptides that still provoke an immune response.
Why it matters
Most peptide cancer vaccines require expensive, time-consuming custom design for each patient. This study shows a way to pre-build a library of peptides that work across many patients. For cancers like CLL that have few mutations, this warehouse model could make peptide vaccines practical and affordable.
The numbers in context
Clinical trial NCT04688385 launched; T cell responses confirmed in CLL patients and healthy volunteers
How the study worked
Researchers collected CLL samples from patients and compared them to a database of normal tissue samples. They used mass spectrometry to identify protein fragments (immunopeptidome) displayed on cancer cell surfaces. They then tested whether these fragments could activate T cells from both CLL patients and healthy people. A phase I clinical trial (NCT04688385) was launched using the resulting peptide warehouse.
Who was studied
CLL patient samples and healthy volunteer blood (human)
What this study cannot tell us
This study describes the workflow and initial immune responses but does not yet show whether the vaccines shrink tumors or extend survival. The clinical trial is still in early stages. The immune responses were measured in lab conditions, and real-world vaccine performance may differ. The sample size of CLL patients analyzed for immunopeptidome data was not large.
How to read the evidence
This is a translational study demonstrating proof-of-concept for a peptide vaccine warehouse approach, with in vitro T cell response data and a clinical trial initiated. Efficacy data from the trial is not yet available.
When this study was published
Published in 2021, the associated clinical trial (NCT04688385) may now have early results. The immunopeptidomics workflow remains current and relevant to the growing field of peptide-based cancer immunotherapy.
The bigger picture
Peptide cancer vaccines have long been considered promising but impractical for widespread use due to the need for personalization. This warehouse approach could change that by making it possible to quickly assemble a patient-specific vaccine from pre-validated components. The strategy is especially valuable for cancers with few mutations — like CLL — where finding unique tumor targets has been a major obstacle. If successful in clinical trials, the workflow could be applied to many other cancer types.
Questions still open
- Will the warehouse peptide vaccines produce clinical responses in the ongoing Phase I trial?
- How many peptides from the warehouse are needed per patient to generate a robust anti-tumor immune response?
- Can this warehouse approach be extended to solid tumors with similarly low mutational burdens?
Common questions
What is a peptide vaccine warehouse and how does it work?
Why is this approach especially useful for CLL?
Read the original research
Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic Leukemia.
Frontiers in immunology, 12, 705974
Citation
Nelde, Annika; Maringer, Yacine; Bilich, Tatjana; Salih, Helmut R; Roerden, Malte; Heitmann, Jonas S; Marcu, Ana; Bauer, Jens; Neidert, Marian C; Denzlinger, Claudio; Illerhaus, Gerald; Aulitzky, Walter Erich; Rammensee, Hans-Georg; Walz, Juliane S. (2021). Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic Leukemia.. Frontiers in immunology, 12, 705974. https://doi.org/10.3389/fimmu.2021.705974